NCT03289455 - CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

May 18, 2020

Study Completion Date

May 18, 2020

Conditions

B Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

AUTO3 (CD19/22 CAR T cells

Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.

Trial Locations (3)

Unknown

Great Ormond Street Hospital for Children NHS Foundation Trust, London

University College London Hospitals NHS Foundation Trust, London

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors

lead

Autolus Limited

INDUSTRY